PROGRESSION FREE SURVIVAL (PFS) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH SECOND LINE ERLOTINIB/GEFITINIB WHO FAILED TO PREVIOUS CHEMOTHERAPY: Abstract ID – 771


    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.


    loading  Loading Related Articles